IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12371503 B1

PDFFull Text
Date of Patent:
Jul. 29, 2025

Filed:

May. 05, 2022

Methods of treatment using a leptin receptor agonist antibody

Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Jesper Gromada, Scarsdale, NY (US);

Panayiotis Stevis, West Orange, NJ (US);

Judith Altarejos, Chappaqua, NY (US);

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Assignee:

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);

Attorneys:

FisherBroyles, LLP

Christy G. Rothwell

Gabriele Amodeo

Primary Examiner:

Elizabeth C Kemmerer

Assistant Examiner:

Regina M Deberry

Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); C07K 14/00 (2006.01); C07K 16/28 (2006.01); A61K 38/22 (2006.01); A61K 39/00 (2006.01); C07K 14/575 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2869 (2013.01); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61K 38/2264 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 14/5759 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Find Patent Forward Citations

Loading…